NBTXR3

About Nanobiotix

Nanobiotix's mission is to transform cancer treatment by developing disruptive, physics-based nanotherapeutics, beginning with its lead radioenhancer candidate, NBTXR3. Key achievements include establishing a pivotal-stage global program in head and neck cancer and securing a landmark strategic collaboration with Janssen (Johnson & Johnson) for NBTXR3's co-development and commercialization. The company's strategy leverages its proprietary nanoparticle platform to create treatments that are biologically agnostic, aiming to improve radiotherapy outcomes and potentially prime anti-tumor immunity across a wide range of solid tumors.

About Nanobiotix

Nanobiotix's mission is to transform cancer treatment by developing disruptive, physics-based nanotherapeutics, beginning with its lead radioenhancer candidate, NBTXR3. Key achievements include establishing a pivotal-stage global program in head and neck cancer and securing a landmark strategic collaboration with Janssen (Johnson & Johnson) for NBTXR3's co-development and commercialization. The company's strategy leverages its proprietary nanoparticle platform to create treatments that are biologically agnostic, aiming to improve radiotherapy outcomes and potentially prime anti-tumor immunity across a wide range of solid tumors.

About Nanobiotix

Nanobiotix's mission is to transform cancer treatment by developing disruptive, physics-based nanotherapeutics, beginning with its lead radioenhancer candidate, NBTXR3. Key achievements include establishing a pivotal-stage global program in head and neck cancer and securing a landmark strategic collaboration with Janssen (Johnson & Johnson) for NBTXR3's co-development and commercialization. The company's strategy leverages its proprietary nanoparticle platform to create treatments that are biologically agnostic, aiming to improve radiotherapy outcomes and potentially prime anti-tumor immunity across a wide range of solid tumors.

About Nanobiotix

Nanobiotix's mission is to transform cancer treatment by developing disruptive, physics-based nanotherapeutics, beginning with its lead radioenhancer candidate, NBTXR3. Key achievements include establishing a pivotal-stage global program in head and neck cancer and securing a landmark strategic collaboration with Janssen (Johnson & Johnson) for NBTXR3's co-development and commercialization. The company's strategy leverages its proprietary nanoparticle platform to create treatments that are biologically agnostic, aiming to improve radiotherapy outcomes and potentially prime anti-tumor immunity across a wide range of solid tumors.

About Nanobiotix

Nanobiotix's mission is to transform cancer treatment by developing disruptive, physics-based nanotherapeutics, beginning with its lead radioenhancer candidate, NBTXR3. Key achievements include establishing a pivotal-stage global program in head and neck cancer and securing a landmark strategic collaboration with Janssen (Johnson & Johnson) for NBTXR3's co-development and commercialization. The company's strategy leverages its proprietary nanoparticle platform to create treatments that are biologically agnostic, aiming to improve radiotherapy outcomes and potentially prime anti-tumor immunity across a wide range of solid tumors.

About Nanobiotix

Nanobiotix's mission is to transform cancer treatment by developing disruptive, physics-based nanotherapeutics, beginning with its lead radioenhancer candidate, NBTXR3. Key achievements include establishing a pivotal-stage global program in head and neck cancer and securing a landmark strategic collaboration with Janssen (Johnson & Johnson) for NBTXR3's co-development and commercialization. The company's strategy leverages its proprietary nanoparticle platform to create treatments that are biologically agnostic, aiming to improve radiotherapy outcomes and potentially prime anti-tumor immunity across a wide range of solid tumors.

About LianBio

LianBio's mission was to accelerate the availability of innovative medicines for patients in China and broader Asian markets by in-licensing clinical-stage assets from global partners. The company built an integrated regional development and commercialization platform to navigate complex regulatory and commercial landscapes. Its primary achievement was advancing a portfolio of promising candidates, including mavacamten for oHCM which reached NDA acceptance in China, before the Board's decision to wind down operations and liquidate the pipeline following a strategic review in November 2023.

Therapeutic Areas